PODD news

Insulet announced Jonathan J. Mazelsky will join its Board as an independent director effective July 1, 2026. Mazelsky’s extensive background in healthcare innovation is expected to bolster the company's strategy for expanding Omnipod access and driving shareholder value.

Insulet Corporation announced a voluntary medical device correction for approximately 7 million Omnipod pods across multiple product lines due to a manufacturing defect causing potential insulin under-delivery, with 24 serious adverse events reported globally including hospitalizations and diabetic …